Evidence mapPaperPMID 35314788Full record

ArticleProstate cancer and prostatic diseases2023

The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study.

V Fay-Watt, S O'Connor, D Roshan, A C Romeo, V D Longo, F J Sullivan

Erratum issued Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04292041 (Fasting Mimicking Diet in Prostate Cancer and Metabolic Syndrome, a Pilot Study), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04292041 unknown statusnot on this map

Fasting Mimicking Diet in Prostate Cancer and Metabolic Syndrome, a Pilot Study

Typeobservational_patient_registrySponsorGalway ClinicRan2019 to 2020Enrolled40ConditionsProstate Cancer, Metabolic Syndrome, Intermittent FastingArmsFasting mimicking diet
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

V Fay-WattSchool of Medicine, National University of Ireland, Galway, Ireland.ORCID 0000-0002-3863-0177
S O'ConnorDepartment of Radiation Oncology, Galway Clinic, Doughiske, Galway, Ireland.
D RoshanSchool of Mathematical and Statistical Sciences, National University of Ireland, Galway, Ireland.
A C RomeoDepartment of Internal Medicine and Medical Specialties, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
V D Longo *IFOM, FIRC Institute of Molecular Oncology, Via Adamello 16, 20139, Milano, Italy.
F J Sullivan *Department of Radiation Oncology, Galway Clinic, Doughiske, Galway, Ireland. frank.sullivan@galwayclinic.com.ORCID 0000-0001-5111-5383
Ollscoil na Gaillimhe – University of Galway · IEGalway Clinic · IEOspedale Policlinico San Martino · ITScience Foundation Ireland · IEUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis pilot prospective study investigated the effect of a periodic fasting mimicking diet (FMD) on metabolic health factors in patients with Prostate Cancer (PC). There is a well-documented association between PC and metabolic health. Impaired metabolic health is a significant risk factor for the development of PC, and a metabolic syndrome can be induced by hormonal therapies commonly required for its management. (ClinicalTrials.gov Identifier: NCT04292041).

methodsWe introduced a periodic 4-day FMD -low in calories, sugars, and proteins but high in unsaturated fats -to a cohort of PC patients and features of metabolic syndrome. 29/35 patients completed 3-monthly cycles of the 4-consecutive day packaged FMD. We compared the subjects' baseline weight, abdominal circumference (AC), blood pressure (BP) and selected laboratory results to the same measurements 3-months after completing the FMD cycles.

resultsSeveral important metabolic factors showed improvements post-intervention. On average patients' weights dropped by 3.79 kg (95% CI: -5.61, -1.97, p = 0.0002). AC was reduced on average by 4.57 cm, (95% CI: -2.27, -6.87, p = 0.0003). There was also a decrease in systolic and diastolic BP by 9.52 mmHg (95% CI: -16.16, -2.88, p = 0.0066) and 4.48 mmHg (95% CI: -8.85, -0.43, p = 0.0316) respectively. A sub-analysis indicates that FMD had more relevant effects in 'at-risk' patients than those with normal values of risk factors for metabolic syndrome. For example, subjects with baseline levels of systolic BP > 130 mmHg experienced a greater reduction in BP(-16.04 mmHg, p = 0.0001) than those with baseline systolic BP < 130 mmHg (-0.78 mmHg, p = 0.89).

conclusionsThe FMD cycles were safely introduced to this small cohort of PC patients with little or no observed toxicity, and a high overall compliance of 83%. Analysis of the metabolic variables showed an overall decrease in weight, AC, and BP. Larger clinical trials focused on metabolic risk factors, PC quality of life and progression free survival are needed to assess the effect of the FMD on prostate cancer patients.

Indexed as

HypertensionMetabolic SyndromeProstatic NeoplasmsBlood PressureDietFastingHumansMalePilot ProjectsProspective StudiesQuality of Life

Identifiers

PMID35314788
PMCPMC10247368
OpenAlexW4220860550

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.